

1. Company details

Name of entity:	EZZ Life Science Holdings Limited
ABN:	83 608 363 604
Reporting period:	For the half-year ended 31 December 2024
Previous period:	For the half-year ended 31 December 2023

2. Results for announcement to the market

			\$
Revenues from ordinary activities	up	39.6% to	30,287,865
Profit from ordinary activities after tax attributable to the owners of EZZ Life Science Holdings Limited	up	179.9% to	3,197,837
Profit for the half-year attributable to the owners of EZZ Life Science Holdings Limited	up	179.9% to	3,197,837

Dividends

	Amount per security Cents	Franked amount per security Cents
Final dividend paid on 9 Dec 2024	2.00	2.00

Comments

The profit for the Group after providing for income tax amounted to \$3,197,837 (31 December 2023: \$1,142,373).

EBITDA (excluding other income) increased by 185% compared with the same period last year as a result of an increase in marketing expenditures.

EBITDA reconciles to profit for the half-year as follows:

	Consolidated 31 December 2024 \$	31 December 2023 \$
Profit for the half-year	3,197,837	1,142,373
Depreciation and amortisation expense	239,021	191,304
Finance costs	7,892	14,226
Interest income	(200,137)	(46,930)
Income tax expense	1,561,266	383,724
EBITDA (excluding other income)	<u>4,805,879</u>	<u>1,684,697</u>

EBITDA is a non-IFRS measure and is presented to enable understanding of the underlying performance without the impact on non-operating items. Non-IFRS measures have not been subject to audit or external review.

3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	<u>50.92</u>	<u>35.78</u>

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Not applicable.

6. Dividends

Current period

	Amount per security Cents	Franked amount per security Cents
Final dividend paid on 9 Dec 2024	2.00	2.00

Previous period

	Amount per security Cents	Franked amount per security Cents
Final dividend paid on 8 Dec 2023	1.00	1.00

7. Dividend reinvestment plans

Not applicable.

8. Details of associates and joint venture entities

Not applicable.

9. Foreign entities

Details of origin of accounting standards used in compiling the report:

On 9 May 2024, the Company incorporated a 100% foreign entity, EZZ Life Science Holdings (USA) Inc., and whilst minimal business has transacted through this entity as at period date 31 December 2024, its financial transactions are recorded in accordance with International Financial Reporting Standards ('IFRS').

10. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements were subject to a review by the auditors and the review report is attached as part of the Interim Report.

11. Attachments

Details of attachments (if any):

The Interim Report of EZZ Life Science Holdings Limited for the half-year ended 31 December 2024 is attached.

12. Signed

Signed _____



Qizhou (Mark) Qin
Executive Director
Sydney

Date: 26 February 2025

For personal use only

EZZ Life Science Holdings Limited

ABN 83 608 363 604

Interim Report - 31 December 2024

For personal use only

Corporate directory	2
Directors' report	3
Auditor's independence declaration	7
Consolidated statement of profit or loss and other comprehensive income	8
Consolidated statement of financial position	9
Consolidated statement of changes in equity	10
Consolidated statement of cash flows	11
Notes to the consolidated financial statements	12
Directors' declaration	19
Independent auditor's review report to the members of EZZ Life Science Holdings Limited	20

For personal use only

Directors	Glenn Cross - Non-Executive Chair Qizhou (Mark) Qin - Executive Director & Chief Executive Officer Ivan Oshry - Non-Executive Director Hao Huang - Non-Executive Director
Company secretaries	Jay Stephenson (appointed on 3 February 2025) Natalie Climo (LLB) (resigned on 3 February 2025)
Registered office and principal place of business	Shop 1 55-59 Parramatta Road Lidcombe NSW 2141 Australia Tel - 02 9160 2305
Share register	Boardroom Pty Limited Level 12 225 George Street Sydney NSW 2000 Australia Tel - 1300 737 760
Auditor	In.Corp Audit & Assurance Pty Ltd Level 1 6-10 O'Connell Street Sydney NSW 2000 Australia
Stock exchange listing	EZZ Life Science Holdings Limited shares are listed on the Australian Securities Exchange (ASX code: EZZ)
Website	www.ezzlife.com.au

For personal use only

The Directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'Group' or 'EZZ') consisting of EZZ Life Science Holdings Limited (referred to hereafter as the 'Company' or 'parent entity') and the entities it controlled at the end of, or during, the half-year ended 31 December 2024.

Directors

The following persons were Directors of EZZ Life Science Holdings Limited during the whole of the financial half-year and up to the date of this report, unless otherwise stated:

Glenn Cross	(appointed on 30 November 2021)
Qizhou (Mark) Qin	(appointed on 1 September 2019)
Ivan Oshry	(appointed on 27 October 2020)
Hao Huang	(appointed on 27 October 2020)

Company secretary

Jay Stephenson (appointed on 3 February 2025)
 Natalie Climo (LLB) (resigned on 3 February 2025)

Principal activities

During the financial half-year the principal continuing activities of the Group consisted of:

- formulation, production, marketing and sale of the EZZ branded health supplements to retailers and consumers domestically and internationally; and
- wholesale distribution of the EAORON branded skin care products to retailers in Australia and New Zealand and direct-to-consumer distribution via a Company operated EAORON e-commerce store.

Dividends

Dividends paid during the financial half-year were as follows:

Consolidated	
31 December 2024	31 December 2023
\$	\$
<u>923,164</u>	<u>427,050</u>

A fully franked final dividend for the year ended 30 June 2024 of 2 cents (2023: 1 cents) per ordinary share was declared on 29 October 2024 and paid on 9 December 2024.

Review of operations

The profit for the Group after providing for income tax amounted to \$3,197,837 (31 December 2023: \$1,142,373).

Revenue from operating activities increased by 39.6% from \$21.7 million in half-year period end 31 December 2023 to \$30.2 million in this half-year period ended 31 December 2024, including the sales from both the EZZ branded health supplements and EAORON branded skincare products.

Revenue from the EZZ branded products increased by 48% on PCP from \$19.1 million to \$28.3 million during the period, which represented 93% of total revenue. The growth was supported by targeted investments in marketing activities. The combination of business-to-consumer ('B2C') and omni-channel digital marketing strategies has continued to drive revenue growth and contributed \$25.7 million in revenue in the half-year period ended 31 December 2024, which represented a 37% growth on PCP. In the half-year period ended 31 December 2024, the Company successfully developed and launched eight new products. Revenue from new products was \$1.2 million, representing 4% of revenue for the half-year period ended 31 December 2024.

Despite hosting a major event celebrating the 10-year anniversary of EAORON during the period, the Group's total advertising expenses remained steady at 53%. The 39% increase in sales resulted in a threefold increase in pre-tax net profit on PCP. This significant growth reflects the effectiveness of our marketing strategies and ongoing operational efficiency improvements.

Gross margin increased to 77% during the period, up from around 70% in the previous corresponding period.

Douyin (China's version of TikTok) remained a key distribution channel in addition to Tmall Global. Douyin related marketing expenditure increased moderately to further expand the Group's social commerce distribution network and support new online distribution points. EZZ is also continuing to invest in marketing in major airports with the resumption of Chinese tourism.

For personal use only

EBITDA (excluding other income) increased by 185% compared with the same period last year due to an increase in marketing expenditures.

EBITDA reconciles to profit for the half-year as follows:

	Consolidated	
	31 December 2024	31 December 2023
	\$	\$
Profit for the half-year	3,197,837	1,142,373
Depreciation and amortisation expense	239,021	191,304
Finance costs	7,892	14,226
Interest income	(200,137)	(46,930)
Income tax expense	1,561,266	383,724
EBITDA (excluding other income)	4,805,879	1,684,697

The Group's cash position remained strong with a closing balance of \$19.9 million as at 31 December 2024, following the distribution of FY24 final dividend. The Group also maintained its debt-free status, with no external debt (other than property lease liabilities) in the half-year period ended 31 December 2024.

Product innovation and launches

Throughout the first half, EZZ launched new products designed to address consumer demand for advanced health and wellness solutions. The eight new products launched in period ended 31 December 2024 were:

- EZZ Immune Defence;
- EZZ Propolis PRO 2000;
- EZZ Glutathione Health Support;
- EZZ Vitality Boost; and
- Four functional food products targeting children and adults.

These products have been well received in both domestic and international markets, reflecting the Company's commitment to maintaining a pipeline of innovative offerings tailored to evolving consumer preferences.

Retail expansion

Domestically, EZZ expanded its retail footprint by securing listings in 14 new independent pharmacies across Australia. This increased accessibility to its product range ensures broader customer engagement and strengthening the Company's distribution network within the Australian market.

Strategic partnerships and brand visibility

EZZ enhanced brand visibility through its strategic partnership with the Australian Open, executing a series of impactful initiatives designed to engage both local and international audiences. The partnership featured:

- a launch event in mainland China, marking a key milestone in EZZ's regional engagement strategy;
- a pre-event content session at Rod Laver Arena in Melbourne, featuring Australian tennis legend Mark Philippoussis; and
- a campaign focused on promoting the Company's children's product range through Australian Open-themed content, distributed across major social media platforms, particularly targeting audiences in China.

In Australia, EZZ also ran a targeted influencer campaign led by renowned fitness expert Jono Castano. The campaign effectively promoted the Company's healthcare products, driving brand engagement and expanding consumer reach.

International growth and US market entry

The Company's international expansion has remained a key focus, with EZZ making progress towards entering the US market. Extensive market research was conducted, including an in-depth product and ingredient analysis of the top 100 best-selling products on Amazon and TikTok. This analysis has guided the development of new products designed to compete with existing competitors in the US market.

The Company's comprehensive market entry plan, developed in collaboration with key agencies, is on track for execution in the second half of FY25. This initiative represents a significant step in EZZ's growth strategy as it seeks to replicate the success of its digital and influencer-driven marketing efforts in other key regions.

Strong performance at the 2024 11.11 Global Shopping Festival

EZZ delivered strong results during the 2024 11.11 Global Shopping Festival, achieving an 84% year-on-year increase in revenue across major marketplaces, including Douyin, Kuaishou, and Tmall. Total revenue during the festival reached \$5.9 million, supported by the Company's KOL partnerships and livestream marketing strategies in China.

Participation in global trade events

EZZ further extended its international presence by participating in the Tax-Free World Association (TFWA) Exhibition and Conference in Dubai. This event enabled the Company to establish connections with prospective buyers and retailers across the Middle East, supporting future growth in the region.

Outlook

Looking ahead, EZZ remains focused on its strategic priorities for the remainder of FY25. In the US, the Company is advancing its market entry plans with a focus on replicating the digital and influencer marketing strategies that have proven successful in other markets.

EZZ is also exploring the potential for expanding its product portfolio into adjacent categories that complement its existing range, ensuring sustainable growth and increased market share. The Company continues to evaluate acquisition opportunities that align with its long-term strategic goals, aiming to deliver enhanced value to shareholders.

Through its proactive approach to innovation, market development, and strategic partnerships, EZZ is well-positioned to build on its momentum and capitalise on emerging opportunities.

General risks

The Company was listed based on its January 2021 Prospectus which did identify a number of specific risks associated with investing in the Group. The Company is addressing the main risks as follows:

- (a) Reliance on customer demand for the EAORON products
 - The Company has the exclusive distribution rights of EAORON products to pharmacies, supermarkets and specialist retailers in Australia and New Zealand, and this brand continues to sell well, especially after the upgraded SKUs released to the market. In the meantime, EZZ continues to release new market favoured products resulting in the EZZ brand generating revenues significantly surpassing EAORON, and dominating the Company's product portfolio.
- (b) Reliance on Distribution Agreement with Australian United Pharmaceuticals Pty Ltd for the EAORON branded products
 - Australian United Pharmaceuticals Pty Ltd is a related party of the Company and the current distribution agreement has been renewed. Further, with EZZ brand generating revenues significantly surpassing those from EAORON product sales, the reliance on the distribution agreement is less of a risk.
- (c) New product risk for the EZZ branded products
 - The Company performs extensive market research when developing new products with 11 products already registered with the USA Food and Drug Administration (FDA). EZZ sales reflect the strong market acceptance of its products.
- (d) End user customers' satisfaction
 - The Company generates most of its sales from B2C via selling on its own official online store on various e-commerce platforms (Douyin, Kuaishou, Tmall, Onion, VipShop, Shopify). The growth in end user customers has resulted in an increased demand for after sales service.
- (e) Reliance on manufacturers
 - The Company raised \$2.46 million as part of the IPO with the intent of bringing the manufacturing process in-house within the intermediate term (two to five years).
- (f) International affairs
 - The Company transacts a majority of its revenue selling into China. The Company's ability to maintain trade in China could be adversely affected by strained political and commercial relations between China and Australia. The Company cannot confirm that these relations will improve in the short to medium term and cannot provide certainty going forward of its ability to trade in China. Further, should the USA's protectionist policies lead to a weakening of China's economic growth, the Chinese Government may impose restrictions or its Chinese citizen's may reduce spending, either of which may impact the Company's ability to sell its products into China.

Significant changes in the state of affairs

There were no significant changes in the state of affairs of the Group during the financial half-year.

Matters subsequent to the end of the financial half-year

No matter or circumstance has arisen since 31 December 2024 that has significantly affected, or may significantly affect the Group's operations, the results of those operations, or the Group's state of affairs in future financial years.

Auditor's independence declaration


A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this Directors' report.

This report is made in accordance with a resolution of Directors, pursuant to section 306(3)(a) of the Corporations Act 2001.

On behalf of the Directors



Glenn Cross
Non-Executive Chair



Qizhou (Mark) Qin
Executive Director

26 February 2025
Sydney

For personal use only

AUDITOR'S INDEPENDENCE DECLARATION UNDER SECTION 307C OF THE CORPORATIONS ACT 2001

To the Directors of EZZ Life Science Holdings Limited

I declare that, to the best of my knowledge and belief, in relation to the review for the half-year ended 31 December 2024 there have been:

- no contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
- no contraventions of any applicable code of professional conduct in relation to the review.

This declaration is in relation to EZZ Life Science Holdings Limited and the entities it controlled during the half-year.

In.Corp Audit & Assurance Pty Ltd



Graham Webb
Director

Sydney, 26 February 2025

In.Corp Audit & Assurance Pty Ltd
ABN 14 129 769 151

Level 1
6-10 O'Connell Street
SYDNEY NSW 2000

Suite 11, Level 1
4 Ventnor Avenue
WEST PERTH WA 6005

GPO BOX 542
SYDNEY NSW 2001

T +61 2 8999 1199
E team@incorpadvisory.au
W incorpadvisory.au

For personal use only

EZZ Life Science Holdings Limited
Consolidated statement of profit or loss and other comprehensive income
For the half-year ended 31 December 2024

EZZ

	Note	31 December 2024 \$	31 December 2023 \$
Revenue	4	30,287,865	21,696,812
Cost of good sold		<u>(6,978,786)</u>	<u>(6,388,728)</u>
Gross profit margin		23,309,079	15,308,084
Interest revenue		200,137	46,930
Expenses			
Advertising and marketing expense		(16,316,660)	(11,733,603)
Employee benefits expense		(764,333)	(559,814)
Depreciation and amortisation expense		(239,021)	(191,304)
Share-based payments expense		(440,722)	(288)
Other expenses		(981,485)	(1,329,682)
Finance costs		<u>(7,892)</u>	<u>(14,226)</u>
Profit before income tax expense		4,759,103	1,526,097
Income tax expense	5	<u>(1,561,266)</u>	<u>(383,724)</u>
Profit after income tax expense for the half-year attributable to the owners of EZZ Life Science Holdings Limited		3,197,837	1,142,373
Other comprehensive income for the half-year, net of tax		-	-
Total comprehensive income for the half-year attributable to the owners of EZZ Life Science Holdings Limited		<u>3,197,837</u>	<u>1,142,373</u>
		Cents	Cents
Basic earnings per share	6	7.07	2.68
Diluted earnings per share	6	7.06	2.68

The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

For personal use only

	Note	31 December 2024 \$	30 June 2024 \$
Assets			
Current assets			
Cash and cash equivalents		19,891,382	19,022,611
Trade and other receivables	7	2,893,981	2,673,648
Inventories		1,539,353	1,401,195
Other current assets	8	4,283,429	1,814,162
Total current assets		28,608,145	24,911,616
Non-current assets			
Property, plant and equipment	9	637,724	502,554
Right-of-use assets	10	475,861	118,965
Intangible assets		20,066	18,848
Total non-current assets		1,133,651	640,367
Total assets		29,741,796	25,551,983
Liabilities			
Current liabilities			
Trade and other payables	11	4,351,965	2,857,259
Lease liabilities	12	354,737	123,856
Current tax liabilities		567,526	1,157,255
Employee benefits		58,288	39,736
Total current liabilities		5,332,516	4,178,106
Non-current liabilities			
Lease liabilities	12	123,855	-
Deferred tax liabilities	5	247,192	51,039
Total non-current liabilities		371,047	51,039
Total liabilities		5,703,563	4,229,145
Net assets		24,038,233	21,322,838
Equity			
Issued capital	13	7,294,974	6,852,670
Reserves		14,383	16,165
Retained earnings		16,728,876	14,454,003
Total equity		24,038,233	21,322,838

	Issued capital \$	Reserves \$	Retained profits \$	Total equity \$
Balance at 1 July 2023	5,998,570	809	8,582,763	14,582,142
Profit after income tax expense for the half-year	-	-	1,142,373	1,142,373
Other comprehensive income for the half-year, net of tax	-	-	-	-
Total comprehensive income for the half-year	-	-	1,142,373	1,142,373
<i>Transactions with owners in their capacity as owners:</i>				
Share-based payments	-	288	-	288
Dividends paid (note 14)	-	-	(427,050)	(427,050)
Balance at 31 December 2023	<u>5,998,570</u>	<u>1,097</u>	<u>9,298,086</u>	<u>15,297,753</u>

	Issued capital \$	Reserves \$	Retained earnings \$	Total equity \$
Balance at 1 July 2024	6,852,670	16,165	14,454,003	21,322,838
Profit after income tax expense for the half-year	-	-	3,197,837	3,197,837
Other comprehensive income for the half-year, net of tax	-	-	-	-
Total comprehensive income for the half-year	-	-	3,197,837	3,197,837
<i>Transactions with owners in their capacity as owners:</i>				
Issue of shares - employee share plan	430,954	-	-	430,954
Performance rights granted	-	9,768	-	9,768
Transfer to retained earnings on expired options	-	(200)	200	-
Transfer to issued capital on exercise of options	11,350	(11,350)	-	-
Dividends paid (note 14)	-	-	(923,164)	(923,164)
Balance at 31 December 2024	<u>7,294,974</u>	<u>14,383</u>	<u>16,728,876</u>	<u>24,038,233</u>

For personal use only

	31 December 2024	31 December 2023
	\$	\$
Cash flows from operating activities		
Receipts from customers	31,236,496	20,037,401
Payments to suppliers and employees	(27,984,235)	(20,180,746)
Interest received	200,137	46,930
Interest and other finance costs paid	(7,892)	(14,226)
Income taxes paid	(1,954,843)	(498,783)
	<u>1,489,663</u>	<u>(609,424)</u>
Net cash from/(used in) operating activities		
Cash flows from investing activities		
Payments for property, plant and equipment	(195,743)	(280,276)
Payments for intangibles	(8,719)	-
Payments for due diligence costs	(60,036)	-
	<u>(264,498)</u>	<u>(280,276)</u>
Net cash used in investing activities		
Cash flows from financing activities		
Dividends paid	(868,611)	(424,441)
Repayment of lease liabilities	(180,608)	(174,274)
	<u>(1,049,219)</u>	<u>(598,715)</u>
Net cash used in financing activities		
Net increase/(decrease) in cash and cash equivalents	175,946	(1,488,415)
Cash and cash equivalents at the beginning of the financial half-year	19,022,611	13,830,751
Effects of exchange rate changes on cash and cash equivalents	692,825	276,038
	<u>19,891,382</u>	<u>12,618,374</u>
Cash and cash equivalents at the end of the financial half-year		

The above consolidated statement of cash flows should be read in conjunction with the accompanying notes

For personal use only

Note 1. General information

The financial statements cover EZZ Life Science Holdings Limited as a Group consisting of EZZ Life Science Holdings Limited and the entities it controlled at the end of, or during, the half-year. The financial statements are presented in Australian dollars, which is EZZ Life Science Holdings Limited's functional and presentation currency.

EZZ Life Science Holdings Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is:

Shop 1
55-59 Parramatta Road
Lidcombe NSW 2141
Australia

A description of the nature of the Group's operations and its principal activities are included in the Directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of Directors, on 26 February 2025.

Note 2. Material accounting policy information

These general purpose financial statements for the interim half-year reporting period ended 31 December 2024 have been prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the Corporations Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 'Interim Financial Reporting'.

These general purpose financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 30 June 2024 and any public announcements made by the Company during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.

The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, unless otherwise stated.

New or amended Accounting Standards and Interpretations adopted

The Group has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period. The adoption of these Accounting Standards and Interpretations did not have any material impact on the financial performance or position of the Group during the financial half-year ended 31 December 2024 and are not expected to have a material impact for the full financial year ending 30 June 2025.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

Note 3. Operating segments

Identification of reportable operating segments

The Group is organised into two operating segments Group on the basis of financial information reported to the Directors which is revenue and gross profit for 'Brought in lines' and 'Company owned' products. These operating segments are based on the internal reports that are reviewed and used by the Board of Directors (who are identified as the Chief Operating Decision Makers ('CODM')) in assessing performance and in determining the allocation of resources. There is no aggregation of operating segments.

The accounting policies adopted for internal reporting to the CODM are consistent with those adopted in the financial statements.

Accounting policies adopted

All amounts reported to the Directors are determined in accordance with accounting policies that are consistent with those adopted in the annual financial statements of the Group.

For personal use only

Note 3. Operating segments (continued)

Segment assets

Assets of the Company are maintained in Australia with the exception of inventory which is stored in a bonded warehouse overseas.

Segment liabilities

Liabilities are generally considered to relate to the Company as a whole and are not allocated.

	Brought in lines \$	Company owned \$	Total \$
31 December 2024			
Revenue	1,954,054	28,333,811	30,287,865
Cost of sales	(1,425,073)	(5,553,713)	(6,978,786)
Gross profit	528,981	22,780,098	23,309,079
	Brought in lines \$	Company owned \$	Total \$
31 December 2023			
Revenue	2,567,051	19,129,761	21,696,812
Cost of sales	(1,810,270)	(4,578,458)	(6,388,728)
Gross profit	756,781	14,551,303	15,308,084

Geographical information

Refer to note 4 for disaggregation of revenue by geographical regions.

Note 4. Revenue

	31 December 2024 \$	31 December 2023 \$
Sale of goods	30,287,865	21,696,812

Disaggregation of revenue

The disaggregation of revenue from contracts with customers is as follows:

	31 December 2024 \$	31 December 2023 \$
<i>Geographical regions</i>		
Australia and New Zealand	4,249,223	3,167,564
Mainland China	23,411,188	18,481,217
Other countries/regions	2,627,454	48,031
	30,287,865	21,696,812
<i>Timing of revenue recognition</i>		
Goods transferred at a point in time	30,287,865	21,696,812

Note 5. Income tax

	31 December 2024	31 December 2023
	\$	\$
<i>Income tax expense</i>		
Current tax	1,365,113	424,849
Deferred tax - origination and reversal of temporary differences	<u>196,153</u>	<u>(41,125)</u>
Aggregate income tax expense	<u>1,561,266</u>	<u>383,724</u>
<i>Numerical reconciliation of income tax expense and tax at the statutory rate</i>		
Profit before income tax expense	<u>4,759,103</u>	<u>1,526,097</u>
Tax at the statutory tax rate of 30% (2023: 25%)	1,427,731	381,524
Tax effect amounts which are not deductible/(taxable) in calculating taxable income:		
Share-based payments	129,286	-
Depreciation and amortisation	280	310
Other non-deductible expenses	<u>3,969</u>	<u>1,890</u>
Income tax expense	<u>1,561,266</u>	<u>383,724</u>
	31 December 2024	30 June 2024
	\$	\$
<i>Deferred tax liability</i>		
Deferred tax liability comprises temporary differences attributable to:		
Amounts recognised in profit or loss:		
Prepayments	12,967	38,901
Net impact of accounting for operating lease	(819)	(1,467)
Depreciation	459	1,077
Employee benefits	(17,486)	(11,921)
Provision for STIP	(2,461)	(3,600)
IPO transaction costs	(22,360)	(44,720)
Accrued expenses	(7,666)	(5,850)
Unrealised foreign exchange loss	296,453	88,316
Superannuation payable	<u>(11,895)</u>	<u>(9,697)</u>
Deferred tax liability	<u>247,192</u>	<u>51,039</u>
Movements:		
Opening balance	51,039	(12,185)
Charged to profit or loss	<u>196,153</u>	<u>63,224</u>
Closing balance	<u>247,192</u>	<u>51,039</u>

For personal use only

Note 6. Earnings per share

	31 December 2024	31 December 2023
	\$	\$
Profit after income tax attributable to the owners of EZZ Life Science Holdings Limited	<u>3,197,837</u>	<u>1,142,373</u>
	Number	Number
Weighted average number of ordinary shares used in calculating basic earnings per share	45,215,782	42,705,000
Adjustments for calculation of diluted earnings per share:		
Options and performance rights over ordinary shares	<u>70,000</u>	<u>-</u>
Weighted average number of ordinary shares used in calculating diluted earnings per share	<u>45,285,782</u>	<u>42,705,000</u>
	Cents	Cents
Basic earnings per share	7.07	2.68
Diluted earnings per share	7.06	2.68

Note 7. Trade and other receivables

	31 December 2024	30 June 2024
	\$	\$
<i>Current assets</i>		
Trade receivables	2,685,740	2,564,580
Other receivables	<u>208,241</u>	<u>109,068</u>
	<u>2,893,981</u>	<u>2,673,648</u>

The carrying value of trade receivables is considered a reasonable approximation of fair value due to the short-term nature of the balances.

The maximum exposure to credit risk at the reporting date is the fair value of each class of receivable in the financial statements.

Note 8. Other current assets

	31 December 2024	30 June 2024
	\$	\$
<i>Current assets</i>		
Prepayments	3,354,934	1,257,671
Security deposits	<u>928,495</u>	<u>556,491</u>
	<u>4,283,429</u>	<u>1,814,162</u>

For personal use only

Note 9. Property, plant and equipment

	31 December 2024	30 June 2024
	\$	\$
<i>Non-current assets</i>		
Leasehold improvements - at cost	456,739	277,489
Less: Accumulated depreciation	<u>(41,621)</u>	<u>(3,184)</u>
	<u>415,118</u>	<u>274,305</u>
Motor vehicles - at cost	156,364	156,364
Less: Accumulated depreciation	<u>(98,775)</u>	<u>(90,471)</u>
	<u>57,589</u>	<u>65,893</u>
Computer equipment - at cost	35,540	25,497
Less: Accumulated depreciation	<u>(17,573)</u>	<u>(13,044)</u>
	<u>17,967</u>	<u>12,453</u>
Office equipment - at cost	162,360	155,910
Less: Accumulated depreciation	<u>(15,310)</u>	<u>(6,007)</u>
	<u>147,050</u>	<u>149,903</u>
	<u>637,724</u>	<u>502,554</u>

Note 10. Right-of-use assets

	Consolidated	
	31 December 2024	30 June 2024
	\$	\$
<i>Non-current assets</i>		
Buildings - right-of-use	535,344	535,344
Less: Accumulated depreciation	<u>(59,483)</u>	<u>(416,379)</u>
	<u>475,861</u>	<u>118,965</u>

Note 11. Trade and other payables

	31 December 2024	30 June 2024
	\$	\$
<i>Current liabilities</i>		
Trade payables	2,688,051	2,077,561
Trade payables - related party (note 15)	1,464,304	655,276
Dividend payable	92,354	37,801
Other payables and accruals	<u>107,256</u>	<u>86,621</u>
	<u>4,351,965</u>	<u>2,857,259</u>

Trade and other payables are unsecured, non-interest bearing and are normally settled within 30 days. The carrying value of trade and other payables is considered a reasonable approximation of fair value due to the short-term nature of the balances.

Note 12. Lease liabilities

	31 December 2024 \$	30 June 2024 \$
<i>Current liabilities</i>		
Lease liability	354,737	123,856
<i>Non-current liabilities</i>		
Lease liability	123,855	-
	<u>478,592</u>	<u>123,856</u>

The Group had total cash outflows for leases of \$188,500 during the half-year ended 31 December 2024 (31 December 2023: \$188,500).

Note 13. Issued capital

	31 December 2024 Shares	30 June 2024 Shares	31 December 2024 \$	30 June 2024 \$
Ordinary shares - fully paid	47,173,200	44,413,200	7,294,974	6,852,670

Movements in ordinary share capital

Details	Date	Shares	Issue price	\$
Balance	1 July 2024	44,413,200		6,852,670
Issue of shares - exercise of performance rights	25 September 2024	10,000	\$0.00	3,100
Issue of shares - employee incentives scheme	30 October 2024	1,735,000	\$3.50	343,831
Issue of shares - exercise of performance rights	25 November 2024	1,000,000	\$2.65	8,250
Issue of shares - employee incentives scheme	6 December 2024	15,000	\$0.00	87,123
Balance	31 December 2024	47,173,200		7,294,974

Note 14. Dividends

Dividends paid during the financial half-year were as follows:

	31 December 2024 \$	31 December 2023 \$
A fully franked final dividend for the year ended 30 June 2024 of 2 cents (2023: 1 cents) per ordinary share was declared on 29 October 2024 and paid on 9 December 2024.	923,164	427,050

Note 15. Related party transactions

Parent entity

EZZ Life Science Holdings Limited is the parent entity.

Note 15. Related party transactions (continued)

Transactions with related parties

The following transactions occurred with related parties:

	31 December 2024	31 December 2023
	\$	\$
Payment for goods and services:		
Purchase of inventory - Australian United Pharmaceuticals Pty Ltd	1,425,073	1,810,270
Payment for other expenses:		
Legal services - Due Books Pty Ltd	-	5,000
Office/warehouse lease - Parramatta Asset Management Pty Ltd	37,000	54,000
Head office premises rent - WM Group Pty Ltd	188,500	188,500

Receivable from and payable to related parties

The following balances are outstanding at the reporting date in relation to transactions with related parties:

	31 December 2024	30 June 2024
	\$	\$
Current payables:		
Trade payables - Australian United Pharmaceuticals Pty Ltd	1,464,304	655,276

Loans to/from related parties

There were no loans to or from related parties at the current and previous reporting date.

Terms and conditions

All transactions were made on normal commercial terms and conditions and at market rates.

Note 16. Contingent liabilities

In the opinion of the Directors, the Group did not have any contingencies at 31 December 2024 (30 June 2024: None).

Note 17. Events after the reporting period

No matter or circumstance has arisen since 31 December 2024 that has significantly affected, or may significantly affect the Group's operations, the results of those operations, or the Group's state of affairs in future financial years.

For personal use only

In the Directors' opinion:

- the attached financial statements and notes comply with the Corporations Act 2001, Australian Accounting Standard AASB 134 'Interim Financial Reporting', the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes give a true and fair view of the Group's financial position as at 31 December 2024 and of its performance for the financial half-year ended on that date; and
- there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of Directors made pursuant to section 303(5)(a) of the Corporations Act 2001.

On behalf of the Directors



Glenn Cross
Non-Executive Chair

26 February 2025
Sydney



Qizhou (Mark) Qin
Executive Director

For personal use only

**EZZ LIFE SCIENCE HOLDINGS LIMITED
INDEPENDENT AUDITOR'S REVIEW REPORT**

To the Members of EZZ Life Science Holdings Limited

Conclusion

We have reviewed the accompanying half-year financial report of EZZ Life Science Holdings Limited, which comprises the consolidated statement of financial position as at 31 December 2024, the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the half-year ended on that date, notes to the financial statements including a summary of material accounting policy information, other explanatory information, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of EZZ Life Science Holdings Limited is not in accordance with the *Corporations Act 2001* including:

- a) giving a true and fair view of the Group's financial position as at 31 December 2024 and of its performance for the half-year ended on that date; and
- b) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

Basis for Conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the Auditor's Responsibilities for the Review of the Financial Report section of our report.

We are independent of the company in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including independence standards)* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical requirements in accordance with the Code.

**In.Corp Audit & Assurance Pty Ltd
ABN 14 129 769 151**

Level 1
6-10 O'Connell Street
SYDNEY NSW 2000

Suite 11, Level 1
4 Ventnor Avenue
WEST PERTH WA 6005

GPO BOX 542
SYDNEY NSW 2001

T +61 2 8999 1199
E team@incorpadvisory.au
W incorpadvisory.au

For personal use only

EZZ LIFE SICENCE HOLDINGS LIMITED

INDEPENDENT AUDITOR'S REVIEW REPORT (continued)

Responsibility of the Directors for the Financial Report

The directors of EZZ Life Science Holdings Limited are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility for the Review of the Financial Report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the company's financial position as at 31 December 2024 and its performance for the half year ended on that date, and complying with AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

In.Corp Audit & Assurance Pty Ltd



Graham Webb
Director

Sydney, 26 February 2025

For personal use only